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Abstract
Purpose The objective of this study is to evaluate quality of
life (QoL) and tolerability of three articles specifically
developed for cancer skin care management (skin moistur-
izer, face moisturizer, and face wash).
Methods Participants were cancer patients (n=99) receiving
systemic anticancer therapies and/or radiotherapy at North-
western University. Subjects were assessed at the initial
visit for adverse skin reactions based on the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events version 3.0 and completed the Skindex-16
questionnaire, a self-reported dermatology-specific QoL
instrument. All subjects were provided with three test
articles and were instructed to use each test article once
daily for 4 weeks. At the 4-week follow-up (n=77), the
Skindex-16 was readministered, adverse skin reactions
were assessed, and tolerability questionnaires were admin-
istered for each article used.
Results Dry skin, hand–foot skin reaction (HFSR), and skin
rash (dermatitis) decreased significantly from baseline to
follow-up. Presence of nail changes, skin rash (desquama-
tion), and acne/acneiform eruptions did not significantly
change from baseline. Subjects had a significantly lower
mean overall Skindex-16 score at 4-week follow-up when
compared to baseline. Most patients rated their overall
experience with each test article as good or very good
(highest rating).
Conclusion Skin care in cancer patients is suboptimal in part
due to a lack of products and knowledge specific for this
population. Our findings suggest that QoL improves with test
article use, all of which were rated as good/very good for
tolerability. Moreover, skin toxicity as manifested by dry
skin, hand-foot skin reaction, and skin rash (dermatitis) were
decreased with use of test articles within 4 weeks.
Keywords Skin care.Chemotherapy.Cancer.Dry skin.
Radiation therapy.Skin irrations.HFSR
Introduction
Patients with various solid and hematologic tumors are
surviving longer and are reporting an enhancement in
quality of life (QoL) with improved anticancer treatments
[1]. However, dermatologic toxicities are noteworthy due to
their high frequency and association with negative symp-
tomatology [2, 3]. Moreover, clinicians and patients report
that dermatologic toxicities have a negative effect on
patients' physical, functional, emotional, and social well-
being [4]. Whereas skin irritation, hair changes, facial
flushing/erythema, and dry skin are common skin reactions
that negatively affect these patients; what may often be
perceived as relatively minor complaints of dry skin, nail
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DOI 10.1007/s00520-010-0851-8changes, and itching are also shown to negatively affect
QoL, at least partly due to their unanticipated nature [5].
Failure to identify and treat these untoward events often
leads to noncompliance or inconsistent administration of
anticancer treatments, all of which may affect clinical
outcome [3, 6, 7]. Consequently, it may often be crucial for
patients undergoing anticancer therapy to proactively
initiate skin care management in order to minimize the
impact of commonly occurring toxicities [8, 9].
Current approaches to skin care management vary widely
and are often based on anecdotal data or poorly controlled
studies. Consequently, one approach has been to simply
recommend that patients moisturize twice daily with thick
emollients [9]. Gentle skin cleansing and maintenance of
hydration of compromised skin may also be an important
element of skin care management during cancer therapies.
Some guidelines, for example, indicate washing with mild
soap and water as routine care for patients receiving radiation
therapy [10]. In a review of two trials assessing skin washing,
both trials found less severe skin reactions to radiation
therapy in washing groups [9, 11]. Various vehicles such as
lotions, creams, and ointments may be recommended, but
clear evidence supporting one product form over another is
lacking [10]. Products that are specifically created for skin
care management during cancer treatment in patients who
may suffer from dermatologic side effects are continuously
being sought to address this unmet need [12].
Since there is insufficient data to evaluate the effective-
ness and tolerability of interventions for cutaneous reac-
tions resulting from anticancer therapies [10], the primary
objective of this study is to evaluate QoL as well as
tolerability of three products developed specifically for skin
care management (skin moisturizer, face moisturizer, and
face wash) during cancer treatments. The secondary
objective of this study is to determine whether a correlation
exists between patient tolerability with skin care manage-
ment and severity of skin toxicity based on the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. The CTCAE is a
standard tool used by clinicians to report cancer treatment
toxicities [13]. We hypothesized that cancer patients with
CTCAE grades 0 or 1 skin toxicity will report improved
QoL if products specifically designed for skin care
management during cancer treatment are utilized.
Methods
Participants in this study were diagnosed cancer patients
receiving cytotoxic chemotherapy, targeted or hormonal
treatments, and/or radiotherapy at the Robert H. Lurie
Comprehensive Cancer Center at Northwestern University
between April and July 2009. A total of 99 subjects
participated (Table 1). The study was approved by the
Northwestern University Institutional Review Board, and
all participants provided written informed consent prior to
participation.
Subjects who agreed to participate were assessed at the
initial visit for adverse skin reactions and graded based on
the NCI-CTCAEv3.0 scale and, in addition, completed the
Skindex-16 questionnaire, a self-reported dermatology-
specific QoL instrument that has undergone reliability and
validity testing in other dermatology conditions such as
acne and psoriasis [14]. All subjects were provided with
three test articles specifically formulated for cancer skin
care management: test article A (skin moisturizer), test
article B (face moisturizer), and test article C (face wash).
Test articles have been developed based on surveys
conducted in cancer patients for preferences of skin
products (Lindi®Skin, Philadelphia, PA). Subjects were
instructed to use each test article once daily for 4 weeks and
to record in a diary the date and time of each test article
application in order to assess level of compliance. Subjects
were interviewed by telephone to assess level of compli-
ance at week2. At the 4-week follow-up interview,
participants completed a follow-up Skindex-16 question-
naire, study personnel assessed cancer treatment-related
skin toxicity according to NCI-CTCAEv3.0 criteria, and a
cancer skin care management tolerability questionnaire
(Fig. 1) was administered for each test article used.
Characteristic % Baseline (n=99) % 4-week follow-up visit (n=74–75) p value
Sex
% males 1 1
Presence of skin toxicity
Dry skin 69 21 <0.0001
Nail changes 5 5 0.99
Rash/desquamation 3 0 0.15
Acne/acneiform 4 7 0.32
Rash: dermatitis 8 2 0.025
HFSR 15 4 0.021
Table 1 Demographic and clin-
ical characteristics
HFSR hand–foot skin reaction
546 Support Care Cancer (2011) 19:545–5543b. If your skin is dry please list the areas of concern 
Product A  4.  What lotions, creams, and/or ointments have you tried in the past 3 
months for skin dryness on hands and feet?  
5.  Compared to other hands and feet moisturizers you have tried which 
statement best describes how well you tolerated this product 
A.  I tolerated this product extremely well, much better than 
other products I have tried 
B.  This product was well tolerated, better than most I have tried
C.  I tolerated this product about the same as others I have tried 
D.  I did not tolerate this product as well as others I have tried 
E.  This product was poorly tolerated on my skin 
Topic
Patient History  1.  Is your main skin concern (please check all that apply)  
           Sensitive skin 
           Redness 
           Dry skin 
           Other 
2.  Do you have a history of rosacea? 
           Yes 
           No 
3.  How would you describe your skin? 
                Very dry 
                Dry 
                Normal 
                Combination (some areas are dry and some are oily) 
               I don’t know 
Question
Fig. 1 Skin care management tolerability questionnaire
Support Care Cancer (2011) 19:545–554 5476.  Compared to other hands and feet moisturizers you have tried, which 
statement best describes the absorption of the product: 
A.  This product easily absorbed readily into my skin, the best 
I have tried 
B.  Product absorbed into my skin better than the other 
products I have tried 
C.  Absorption was about the same as the other products I 
have tried 
D.  Not quite as good as the other products at absorption 
E.  Did not absorb into my skin at all 
7.  Compared to other hands and feet moisturizers you have tried, which 
statement best describes the soothing properties of this product: 
A.  Soothed my skin much better than other products I have 
tried 
B.  Soothed my skin better than other products I have tried 
C.  Soothed my skin about the same as other products I have 
tried 
D.  Not quite as soothing as the other products I have tried 
E.  Was not soothing at all or the first product I have tried 
8.  How would you rate your overall experience with the product? 
A. Very  good 
B. Good 
C. Okay 
D. Bad 
E. Very  bad 
9.  Please list any additional comments regard test article A in the space 
provided below. 
Fig. 1 (continued)
548 Support Care Cancer (2011) 19:545–554Product B  10. What face lotions and/or creams have you tried in the past 3 months?  
11. Compared to other facial moisturizers you have tried, which statement 
best describes the decrease in redness you noticed when using this 
product: 
A.  This product was much better at decreasing the appearance 
of my redness than others I have tried 
B.  This product was slightly or somewhat better at decreasing 
the appearance of my redness than the others I have tried 
C. About  the  Same 
D.  Not quite as good 
E.  Did not notice any redness reduction at all 
12. Compared to other facial moisturizers you have tried, which statement 
best describes the amount of dryness relief you experienced with this 
product: 
A.  Much better than the others I have tried 
B.  Somewhat better than the others I have tried 
C.  Relived my dryness about as well as the other products I 
have tried 
D.  Not quite as well 
E.  No or minimal dryness relief from this product, compared to 
the others 
13. Compared to other facial moisturizers you have tried, which statement 
best describes the improvement in the overall appearance of my skin 
while using this product: 
A.  My skin appeared greatly improved 
B.  My skin appeared to look somewhat improved 
C.  My skin appeared to look about the same 
D.  My skin did not appear to look as good 
E.  My skin looked worse than while using other products 
Fig. 1 (continued)
Support Care Cancer (2011) 19:545–554 54914. How would you rate your overall experience with the product? 
A. Very  good 
B. Good 
C. Okay 
D. Bad 
E. Very  bad 
15. Please list any additional comments regard test article B in the space 
below. 
Product C  16. What facial cleansers have you used in the past 3 months? 
17. Compared to other facial cleansers you have tried, which statement 
best describes how well your skin tolerated this product? 
A.  I tolerated this product extremely well, much better than other 
products I have tried 
B.  This product was well tolerated, better than most I have tried 
C.  I tolerated this product about the same as others I have tried 
D.  I did not tolerate this product as well as others I have tried 
E.  This product was poorly tolerated on my skin 
18. Compared to other facial cleansers you have tried, which statement 
best describes the gentleness of this product: 
A.  Much better than the others I have tried 
B.  Somewhat better than the others I have tried 
C.  About as gentle as the other products I have tried 
D.  Not quite as gentle as others I have tried 
E.  Much less gentle than others I have tried 
Fig. 1 (continued)
550 Support Care Cancer (2011) 19:545–554Grading of dermatologic adverse events
Severity of cancer treatment-related skin toxicity was
assessed by the research staff using the NCI-CTCAEv3.0.
The CTCAE is used to report and grade severity of toxicity
in trials of anticancer agents [15]. According to NCI-
CTCAE, grades 2, 3, or 4 require medical intervention [13].
Therefore, subjects with grades 2, 3, or 4 skin toxicities
were excluded from this study. Grade 0 refers to no skin
toxicity for purposes of this study [13]. Therefore, selection
criteria for this study included oncology patients receiving
chemotherapy or radiotherapy with a skin toxicity of 0–1
based on the NCI-CTCAEv3.0 scale.
Assessment of quality of life using the Skindex-16
Skindex is a 16-question quality of life instrument that has
been validated to accurately measure the extent patients are
bothered by certain skin conditions [14]. Each question
asks subjects the degree to which they have been concerned
by their specific skin condition in the week prior to
administration of the questionnaire. Subjects answer every
question with a number ranging from 1 (never bothered) to
6 (always bothered). After Skindex-16 is complete,
responses to each item are transformed to a linear scale of
100, varying from 0 (never bothered) to 100 (always
bothered). Thus, each item has a minimum score of 0 and a
maximum score of 100. In this study, Skindex-16 is
recorded for the baseline visit and the 4-week follow-up
interview (16 individual scores) and three groupings of the
16 questionnaire scores as domains: symptoms, emotions,
and function. The symptoms (items 1–4), emotions (items
5–11), and function (items 12–16) domains are scores
calculated as means ranging from 0 to 100 [15].
Statistical analysis
Fisher’s exact test was used to assess the change in toxicity
rates between baseline and follow-up. The Skindex-16 was
compared between the baseline visit and follow-up inter-
view using a repeated measures analysis of variance taking
into account that some patients had data at two time points
and others only had baseline data. This is an overall
evaluation of all three test articles used for skin care
management and is not specific to each test article. In order
to be considered as improved QoL, the mean Skindex-16
score must decrease between the two time points. Analysis
is done for the overall scale as well as for the three domains
(symptoms, emotions, and function). Fisher’s exact test was
used to compare product satisfaction across products in
patients with rosacea. Fisher’s exact test was also used to
relate product satisfaction to skin type.
Results
Of 99 enrolled subjects, 77 completed the four-week
assessment. Twenty-two subjects withdrew consent or were
lost to follow-up. Two subjects provided incomplete
questionnaires resulting in a n=75 for analytical purposes.
Sample sizes for follow-up results varied due to missing
data for certain questionnaire items.
19. How would you rate your overall experience with the product? 
A. Very  good 
B. Good 
C. Okay 
D. Bad 
E. Very  bad 
20. Please list any additional comments regarding test article C in the 
space provided below. 
Fig. 1 (continued)
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Most subjects (69%, n=75) experienced dry skin at
baseline and 21% (n=75) at study completion (4 weeks;
p<0.0001, Table 1). Of the 11 subjects who presented with
HFSR at baseline visit (15% of 75), three continued to have
HFSR present at 4-week follow-up (4% of 75, p=0.021).
Skin rash (dermatitis) decreased from 8% (n=75) at
baseline to 1% (n=75) at 4-week follow-up (p=0.025).
Few subjects had nail changes (5% of 74), rash (desqua-
mation; 3% of 75), and acne/acneiform eruptions (4% of
75) at the initial visit, and presence of these toxicities did
not significantly change from baseline to 4 week follow-up
(5% of 75 p=0.99, 0% of 75 p=0.15, 7% of 75 p=0.32,
respectively).
Dermatology-related quality of life improvement at follow-up
The study population at 4-week follow-up had a mean
overall Skindex-16 score of 16.19, which is lower than
baseline of 25.05 (p=0.0003). Each domain (symptoms,
emotions, function) also had a significant decrease in the
mean Skindex-16 domain score from baseline to follow-up;
symptoms domain value decreased from 25.21 to 17.05
(p=0.0085), emotions decreased from 32.24 to 20.22
(p=0.0002), function from 15.02 to 9.87 (p=0.008; Table 2,
Fig. 2).
Cancer skin care management survey
Test article A: skin moisturizer
Although a high percentage of the 75 evaluable participants
(n=72, 96%) had used other products for chemotherapy-
associated dry skin, 63% (n=47) tolerated test article A
better than previous other products. Nearly 30% (n=22) of
participants reported tolerating test article A about the same
as other products previously tried. A majority of subjects
(n=49, 65%) said the test article vanished into the skin
better than other previous moisturizers. Most participants
(n=44, 59%) found the test article to soothe the skin better
than other products tried for dry skin, and 31% (n=23)
reported the test article soothed the skin about the same as
other products tried (Table 3). The majority of subjects,
79% (n=59), rated their overall experience with the test
article as good or very good (Table 4).
Test article B: face moisturizer
Of the 77 participants who completed the study, 73 (95%)
subjects used up to three other products to decrease redness
and soothe compromised skin on the face within 3 months
prior to study initiation. A majority of participants (n=54,
70%) saw improvement in overall appearance of their facial
skin while using test article B compared to other facial
moisturizers they had previously tried. Compared to other
products used in the past, 70% (n=54) of subjects reported
that their facial skin appeared to look as good or better with
use of test article B. Of participants experiencing erythema at
study initiation, 55% (n=32/58) of participants experienced a
more pronounced decrease in facial erythema with the use of
test article B compared to previous products. Moreover, most
participants (n=58, 75%) also experienced enhanced relief of
dryness with test article B compared to other products
previously used for dry skin of the face (Table 3). A high
majority, 88% (n=68) of participants, rated their overall
experience with test article B as good or very good (Table 4).
Test article C: face wash
Nearly all participants (n=73, 97%) used one or two other
facial cleansers for toxicity related to facial skin within
3 months prior to study initiation. A majority of participants
Domain Baseline 4-week follow-up visit p value
n value Mean n value Mean
Symptoms 98 25.21 77 17.05 0.0085
Emotions 98 32.24 77 20.22 0.0002
Function 97 15.02 77 9.87 0.008
Combined (All) 98 25.05 77 16.19 0.0003
Table 2 Skindex-16: quality of
life subscale domains
Fig. 2 Change in Skindex-16 scores from baseline to 4-week follow-up
552 Support Care Cancer (2011) 19:545–554(n=46, 62%) tolerated test article C better than other facial
cleansers. Most participants (n=50, 67%) rated test article
C as more gentle, and 32% (n=24) rated product C as about
as gentle compared to other products (Table 3). In general,
74% (n=56) of subjects rated their overall experience with
test article C as good or very good (Table 4).
Tolerability for participants with pre-existing rosacea
Twelve (16%) of the evaluable participants (n=74) using test
article A reported pre-existing rosacea. A majority of
participants (n=10, 83%, 95% CI 61–95%) presenting with
pre-existing rosacea indicated that test article A was very
good or good. Of the 12 subjects with rosacea, 11 indicated
that test article B was very good or good (92%, 95% CI 73–
98%). Of the12 subjects with rosacea, nine or 75% (95% CI
51–91%) indicated that test article C was very good or good.
AF i s h e r ’s exact test to compare cancer skin care manage-
ment satisfaction by patients with pre-existing rosacea across
all three test articles (A, B, and C) indicated similar
acceptability (p=0.85, when comparing 83%, 92%, 75%).
Skin type versus product satisfaction
A correlation was not found by examining skin type (very
dry/dry, normal, combination/do not know) versus product
satisfaction. Satisfaction with the skin moisturizer (test
article A) across skin types (n=73) did not vary by skin
type (p=0.82 by Fisher’s exact test). Satisfaction with the
facial moisturizer (test article B) across skin types was not
significant (n=75, p=0.71). Lastly, satisfaction with test
article C compared across subject skin types was not
different (p=0.40, n=74).
Discussion
Dermatologic toxicities are common side effects associated
with anticancer treatments, and these adverse events often
negatively impact a patient’s quality of life and willingness
to continue with treatment [3]. Management of these events
in cancer patients is suboptimal in part due to the lack of
products specifically designed for this patient population. In
seeking to investigate the tolerability and effects on quality
of life for products designed for cancer skin care manage-
ment, these findings suggest that quality of life, as
measured by Skindex-16, improves with products specifi-
cally designed for cancer skin care management. Moreover,
the severity of skin toxicity graded according to CTCAE
decreases within 1-month use of products specifically de-
signed for cancer skin care management, and dermatology
quality of life significantly improves as early as 1 month for
individual domains (symptoms, emotions, functions).
Table 3 Cancer skin care management survey
Test article A
a Test article B
b Test article C
c
Tolerability
(n=75)
Absorption
(n=75)
Soothing
properties
(n=75)
Redness
reduction
(n=58)
d
Dryness
relief
(n=77)
Improvement in
appearance
(n=77)
Tolerability
(n=74)
Gentleness
(n=75)
Very good,
good
47 (62.67%) 49 (65.33%) 44 (58.67%) 32 (55.17%) 58 (75.32%) 54 (70.13%) 46 (62.16%) 50 (66.67%)
About the
same
22 (29.33%) 14 (18.67%) 23 (30.67%) 14 (24.24%) 11 (14.29%) 20 (25.97%) 24 (32.43%) 24 (32.00%)
Bad, very
bad
6 (8.00%) 12 (16.00%) 8 (10.67%) 12 (20.69%) 8 (10.39%) 3 (3.90%) 4 (5.41%) 1 (1.33%)
aSkin moisturizer
bFacial moisturizer
cFacial wash
d41 patients did not have any redness initially
Table 4 Cancer skin care management survey: overall experience in patients
Overall experience Skin moisturizer (test article A) Face moisturizer (test article B) Face wash (test article C)
n=75 % n=77 % n=76 %
Very good, good 59 78.67 68 88.31 56 73.68
Okay 12 16.00 7 9.09 18 23.68
Bad, very bad 4 5.33 2 2.60 2 2.63
Support Care Cancer (2011) 19:545–554 553This study demonstrates that products specifically
designed for cancer skin care management improve skin-
related quality of life. Moreover, patients with rosacea and
rosacea-like erythematous facial skin are often very sensitive
to skin care products that can worsen inflammation and
produce irritation [16]. This study demonstrated cancer
patients with pre-existing rosacea tolerate test articles A, B,
and C. Maintenance of cutaneous integrity during cancer
treatments with the use of moisturizers may aid in mitigating
dry skin, which may be associated with pruritus and
infections, minimizing these comorbidities [17, 18].
In summary, specifically tailored skin care management
for cancer patients is well tolerated by patients currently
undergoing anticancer therapy or radiation, and a majority
of subjects report that such therapies are better than
previous regimens used. A majority of participants also
report improved dermatology QoL. Previous studies indi-
cate that dermatology QoL rebounds within 4 months of
completion of anticancer regiments, making it important for
patients to receive interventions during anticancer therapy
and the immediate 4-month follow-up period [19].
Advance knowledge of side effects and proactive man-
agement approaches have been shown to decrease anxiety,
improve adherence to cancer treatment, and improve QoL
and patient outcomes [5]. Studies suggest that anticancer
therapy side effects are less anxiety provoking when
anticipated [20]. If patients engage in anticipatory coping, a
mechanism involving “affective and behavioral rehearsal,”
patients feel in control when toxicities resulting from cancer
treatments arise [21]. A cancer skin care management
program fulfills patient engagement of anticipatory coping
in order to optimally anticipate and control cutaneous side
effects associated with anticancer therapy.
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